Request an invite

Ziihera: how long were the pivotal tox studies?

zanidatamab · HER2 x HER2 (biparatopic)
Longest pivotal study
13 weeks
“A comprehensive series of non-GLP and GLP studies have been conducted. The program included tissue cross-reactivity studies in panels of human tissues and IV toxicology studies of up to 13 treatment cycles (13 weeks duration) performed in cynomolgus monkeys.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Pivotal GLP studies
GLP cynomolgus 13-week weekly IV infusion study (8-week interim, 8-week recovery), 5/50/150 mg/kg
“Doses of 0 (vehicle control), 5, 50, and 150 mg/kg QW Route of administration: 1 hour IV infusion Formulation/Vehicle: sucrose, pH Species/Strain: Cynomolgus monkey”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
Route in tox
IV infusion
“Intravenous dosing was utilized in all pivotal toxicology studies since it is the intended route of administration in the clinic.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗

Same question, other bispecifics

Bizengri

zenocutuzumab · HER2 x HER3
13 weeks

Blincyto

blinatumomab · CD19 x CD3
13 weeks

Columvi

glofitamab · CD20 x CD3
4 weeks

Elrexfio

elranatamab · BCMA x CD3
13 weeks

Epkinly

epcoritamab · CD20 x CD3
5 weeks

Kimmtrak

tebentafusp · CD3 x gp100 (TCR fusion)
0 (no in vivo tox study)

Korjuny

catumaxomab · EpCAM x CD3
0 (no in vivo tox study)

Lunsumio

mosunetuzumab · CD20 x CD3
26 weeks

Ordspono

odronextamab · CD20 x CD3
16 weeks

Removab

catumaxomab · EpCAM x CD3
0 (no in vivo tox study)

Talvey

talquetamab · GPRC5D x CD3
4 weeks

Tecvayli

teclistamab · BCMA x CD3
5 weeks

Vabysmo

faricimab · VEGF-A x Ang-2
26 weeks

Summary across all 18 bispecifics →